ASCO 2022 Conference Coverage

June 9, 2022

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

F. de Marinis

ASCO 2022 Conference Coverage

F. de Marinis

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

L. Mazzeo, M. Occhipinti

ASCO 2022 Conference Coverage

J. Goldschmidt

ASCO 2022 Conference Coverage

J. Goldschmidt

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

Login

Login

Join VuMedi

ASCO 2022 Conference Coverage

ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in SCLC and Intracranial Metastatic Disease: A Systematic Review and Meta-Analysis

Lecture Summary - ASCO 2022 Five-Year Survival Outcomes From CheckMa…

ASCO 2022 Five-Year Survival Outcomes From CheckMate 227: Nivo + Ipi…

Lecture Summary - ASCO 2022 on the Phase 3 AcceleRET Lung Study: 1L …

ASCO 2022 on the Phase 3 AcceleRET Lung Study: 1L Pralsetinib in RET…

Lecture Summary - Pralsetinib in Patients (pts) With Advanced or Met…

ASCO 2022 Updated Data From the ARROW Trial: Pralsetinib in Patients…

Lecture Summary - ASCO 2022 3-Year Update From CheckMate 9LA: 1L Niv…

ASCO 2022 3-Year Update From CheckMate 9LA: 1L Nivo + Ipi + 2 Cycles…

ASCO 2022 Immunotherapy Nuances in Locally Advanced NSCLC

Lecture Summary - ASCO 2022 Immunotherapy Nuances in Locally Advance…

ASCO 2022 on Acquired EGFR-Resistant Mutations in NSCLC

Lecture Summary - ASCO 2022 on Acquired EGFR-Resistant Mutations in …

Lecture Summary - ASCO 2022 on Recurrent SCLC: Can We Change the Par…

Lecture Summary - ASCO 2022 on Durvalumab +/- Tremelimumab + Chemo i…

ASCO 2022 on Durvalumab +/- Tremelimumab + Chemo in 1L mNSCLC: AE Ma…

ASCO 2022 on IO and Chemo-IO for NSCLC With Novel Actionable Oncogen…

Lecture Summary - ASCO 2022 Impact of Trilaciclib on Multilineage Ch…

ASCO 2022 Impact of Trilaciclib on Multilineage Chemo-Induced Myelos…

ASCO 2022 Predictors of Biomarker Testing Among Pts With mNSCLC

ASCO 2022 on a Phase I, Open-Label, Dose Escalation, Confirmation, a…

Lecture Summary - ASCO 2022 on a Phase I, Open-Label, Dose Escalatio…

Taking on Goliath: Targeting KRAS in NSCLC

ASCO 2022 on Phase 3 ATLANTIS Trial: Analysis of Patients With Relap…

ASCO 2022 on Telisotuzumab Vedotin in Advanced c-Met Overexpressing …

Lecture Summary - ASCO 2022 Analysis of Patients With Relapsed SCLC …

Lecture Summary - ASCO 2022 on Telisotuzumab Vedotin in Advanced c-M…

ASCO 2022 on TROPION-Lung08: Dato-DXd + Pembro in Treatment-Naïve Ad…

Lecture Summary - ASCO 2022 on ctDNA Shed as a Tool to Select Immune…

Lecture Summary - ASCO 2022 Combi-TED: A Multicenter Phase II Trial …

ASCO 2022 Combi-TED: A Multicenter Phase II Trial Evaluating Efficac…

Lecture Summary - ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in…

ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in SCLC and Intracra…

Lecture Summary - ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Stud…

ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolim…

Lecture Summary - ASCO 2022 on Clinical and Genomic Characteristics …

ASCO 2022 on Clinical and Genomic Characteristics of Pts With Durabl…

Lecture Summary - ASCO 2022 Three-Year Outcomes and Correlative Anal…

ASCO 2022 Three-Year Outcomes and Correlative Analyses in Patients W…

ASCO 2022 on GEOMETRY-N Trial: Neoadjuvant and Adjuvant Capmatinib i…